Related Experiment Video
Updated: Jan 25, 2026

Differentiation of a Human Neural Stem Cell Line on Three Dimensional Cultures, Analysis of MicroRNA and Putative Target Genes
Published on: April 12, 2015
EGF and IGF1 affect sunitinib activity in BP-NEN: new putative targets beyond VEGFR?
Giulia Bresciani1, Angeliki Ditsiou2, Chiara Cilibrasi2
1Section of Endocrinology and Internal Medicine, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
Abstract:
Broncho-pulmonary neuroendocrine neoplasms (BP-NENs) are neoplasms orphan of an efficient therapy. Available medical treatments derived from clinical trials are not specific for the management of this malignancy. Sunitinib is a multi-receptor tyrosine-kinases (RTKs) inhibitor that has already shown its efficacy in NENs, but there are no available data about its action in BP-NENs. Therefore, our aim was to understand the effects of RTKs inhibition promoted by sunitinib in order to evaluate new putative targets useful in malignancy treatment. Since our results underlined a role for EGFR and IGF1R in modulating sunitinib antiproliferative action, we investigated the effects of erlotinib, an EGFR inhibitor, and linsitinib, an IGF1R inhibitor, in order to understand their function in regulating cells behaviour. Cell viability and caspase activation were evaluated on two immortalised human BP-NEN cell lines and primary cultures. Our results showed that after treatment with sunitinib and/or IGF1, EGF and VEGF, the antiproliferative effect of sunitinib was counteracted by EGF and IGF1 but not by VEGF. Therefore, we evaluated with AlphaScreen technology the phosphorylated EGFR and IGF1R levels in primary cultures treated with sunitinib and/or EGF and IGF1. Results showed a decrease of p-IGF1R after treatment with sunitinib and an increase after co-treatment with IGF1. Then, we assessed cell viability and caspase activation on BP-NEN cell lines after treatment with linsitinib and/or erlotinib. Results demonstrate that these two agents have a stronger antiproliferative effect compared to sunitinib. In conclusion, our results suggest that IGF1R and EGF1R could represent putative molecular targets in BP-NENs treatment.
Insights
Targeting epidermal growth factor receptor (EGFR) and insulin-like growth factor 1 receptor (IGF1R) shows promise for treating broncho-pulmonary neuroendocrine neoplasms (BP-NENs). These targeted therapies offer a more effective approach than current treatments for BP-NENs.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Broncho-pulmonary neuroendocrine neoplasms (BP-NENs) lack effective targeted therapies.
- Sunitinib, a multi-receptor tyrosine kinase (RTK) inhibitor, shows efficacy in other neuroendocrine neoplasms (NENs) but its role in BP-NENs is unestablished.
Purpose of the Study:
- To investigate the effects of RTK inhibition by sunitinib in BP-NENs.
- To identify potential molecular targets for BP-NENs treatment by examining the roles of EGFR and IGF1R.
Main Methods:
- Evaluated cell viability and caspase activation in BP-NEN cell lines and primary cultures.
- Utilized AlphaScreen technology to measure phosphorylated EGFR and IGF1R levels.
- Assessed the effects of sunitinib, erlotinib (EGFR inhibitor), and linsitinib (IGF1R inhibitor).
Main Results:
- Sunitinib's antiproliferative effect was counteracted by EGF and IGF1, but not VEGF.
- Sunitinib treatment decreased p-IGF1R, while co-treatment with IGF1 increased it.
- Erlotinib and linsitinib demonstrated a stronger antiproliferative effect than sunitinib in BP-NEN cell lines.
Conclusions:
- EGFR and IGF1R signaling pathways play a role in modulating sunitinib's efficacy in BP-NENs.
- Targeting IGF1R and EGFR with specific inhibitors like linsitinib and erlotinib shows significant antiproliferative potential for BP-NENs treatment.
More Related Videos
04:27Using Facial Electromyography to Assess Facial Muscle Reactions to Experienced and Observed Affective Touch in Humans
Published on: March 15, 2019
11:37Using Sniper-Cas9 to Minimize Off-target Effects of CRISPR-Cas9 Without the Loss of On-target Activity Via Directed Evolution
Published on: February 26, 2019
Related Concept Videos
Role of Affect in Interpersonal Attraction
The Influence of Affect on Cognition
The Influence of Cognition on Affect
Background and Environment Affect Phenotype
An example of how genetic background affects phenotype can be seen in horses. The Extension gene in horses is responsible for their coat color. A wild-type gene (EE) produces black pigment in the coat, while a mutant gene (ee) produces red pigment. A...
Co-activators and Co-repressors
tRNA Activation